RecruitingPhase 4NCT05849740

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

Studying Acquired Hemophilia

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator: Lei Zhang
Chinese Academy of Medical Science and Blood Disease Hospital
Intervention: Daratumumab and corticosteroid treatment(drug)
Enrollment: 25 enrolled
Eligibility: 18 years · All sexes
Timeline: 2023 – 2027

Study locations (1)

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05849740 on ClinicalTrials.gov

← Back to all trials